HomeBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Previous close
CHFÂ 41.15
Day range
CHFÂ 40.60 - CHFÂ 41.45
Year range
CHFÂ 32.00 - CHFÂ 49.00
Market cap
540.62M CHF
Avg Volume
17.18K
P/E ratio
47.10
Dividend yield
-
Primary exchange
SWX
Market news
Financials
Income Statement
Revenue
Net income
(CHF) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 36.36M | -19.30% |
Operating expense | 7.96M | 12.34% |
Net income | -10.69M | -187.82% |
Net profit margin | -29.41 | -208.81% |
Earnings per share | — | — |
EBITDA | -7.88M | -152.08% |
Effective tax rate | 0.08% | — |
Balance Sheet
Total assets
Total liabilities
(CHF) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 59.93M | -29.21% |
Total assets | 173.29M | -21.53% |
Total liabilities | 183.29M | -24.12% |
Total equity | -10.00M | — |
Shares outstanding | 12.00M | — |
Price to book | -49.58 | — |
Return on assets | -11.81% | — |
Return on capital | -17.26% | — |
Cash Flow
Net change in cash
(CHF) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -10.69M | -187.82% |
Cash from operations | -3.81M | -210.31% |
Cash from investing | -322.50K | -100.69% |
Cash from financing | -20.11M | -4.52% |
Net change in cash | -24.31M | -178.80% |
Free cash flow | -4.62M | -154.24% |
About
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
CEO
Founded
Oct 2000
Website
Employees
147